Merck KGaA (FRA:MRK) has been given a €94.00 ($109.30) target price by investment analysts at Nord/LB in a note issued to investors on Friday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s price objective indicates a potential downside of 0.91% from the stock’s current price.
Several other brokerages have also recently issued reports on MRK. Independent Research set a €106.00 ($123.26) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Wednesday, June 19th. Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Thursday. Warburg Research set a €103.00 ($119.77) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Morgan Stanley set a €96.00 ($111.63) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, June 18th. Finally, Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Monday, June 17th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of €100.05 ($116.34).
FRA MRK traded up €0.30 ($0.35) during trading hours on Friday, reaching €94.86 ($110.30). The company’s stock had a trading volume of 484,060 shares. The business’s 50-day moving average is €93.46. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Key terms to understand channel trading
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.